Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Withdrawn) A method of treating a patient suffering from substance abuse comprising administering to the patient medication that includes a dose of clozapine, risperidone or both, effective to reduce abuse.

2. (Withdrawn) A method of treating a patient suffering from substance abuse comprising administering to the patient medication effective to strongly antagonize α2 andrenergic receptors and to weakly antagonize dopamine D2 receptors.

3. (Withdrawn) A method of treating, a patient suffering from substance abuse comprising administering to the patient medication effective to rectify an abuse-associated dysfunction in the DA-mediated brain reward circuit.

4. (Withdrawn) The method of any one of claims 1-3 in which the patient is not schizophrenic.

5. (Withdrawn) The method of any one of claims 1-3 in which the medication comprises clozapine.

6. (Withdrawn) The method of claim 3 in which the medication comprises:
a first component which weakly blocks the D2 receptor; and
a second component which strongly blocks α2 receptors.

7. (Withdrawn) The method of claim 6 in which the first component is selected from clozapine, risperidone, olanzapine, quetiapine and ziprasidone.

8. (Withdrawn) The method of claim 6 or 7 in which the second component is idazoxan, or another α2 receptor antagonist.

9. (Withdrawn) The method of claim 2 in which the medication is formulated as a single dose comprising both the first and the second components.

10. (Withdrawn) The method of claim 2 or 3 in which the medication is characterized by a ratio of α2 blockade: D2 receptor blockade similar to that of clozapine.

11. (Withdrawn) The method claim 10 in which the medication is characterized by a ratio of α2C blockade: D2 receptor blockade similar to that of clozapine.

12. (Withdrawn) The method of claim 6 in which the medication strongly blocks the a2C receptor.

13. (Original) A cocktail comprising
a first component which weakly blocks the D2 receptor; and
a strong α2 receptor antagonist.

14. (Previously Presented) The cocktail of claim 13 in which the first component is selected from clozapine, risperidone, olanzapine, quetiapine and ziprasidone.

15. (Previously Presented) The cocktail of claim 13 or 14 in which the second component is idazoxan, or another α2 receptor antagonist.

16. (Previously Presented) The cocktail of claim 13 or 14 in which the cocktail is characterized by strong blockade of the α2C receptor.

17. (Previously Presented) The cocktail of claim 13 or 14 in which the cocktail is characterized by a ratio of α2 blockade: D2 receptor blockade similar to that of clozapine.

18. (Withdrawn) The method claim 12 in which the cocktail is characterized by a ratio of α2C blockade: D2 receptor blockade similar to that of clozapine.

19. (Withdrawn) The method of any one of claims 1-3 wherein the substance is alcohol.

20. (New) The cocktail of claim 13 comprising idazoxan.

21. (New) The cocktail of claim 13 comprising quetiapine.

22. (New) The cocktail of claim 13 comprising idazoxan and quetiapine.